

TN
100 Covey Drive
Suite 307
Franklin, TN 37067



VIMIZIM[®] (elosulfase alfa)

ORDER FORM

Date: _____

PATIENT INFORMATION			
Name:	Phone:	DOB:	SEX: M <input type="checkbox"/> F <input type="checkbox"/>
<input type="checkbox"/> NKDA Allergies:		Weight lbs/kg:	
PHYSICIAN INFORMATION			
Physician Name*:		Practice Name:	
Address:		Office Contact Name:	Office Contact #:
Phone:	Fax:	Email (for updates):	
REFERRAL STATUS			
<input type="checkbox"/> New Referral <input type="checkbox"/> Referral Renewal <input type="checkbox"/> Medication/Order Change <input type="checkbox"/> Benefits Verification Only <input type="checkbox"/> Discontinuation Order			

VIMIZIM[®]:

VIMIZIM is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). E76.210

DOSAGE AND ADMINISTRATION:

Recommended Dose
Pre-treatment with antihistamines with or without antipyretics is recommended 30 to 60 minutes prior to the start of the infusion.

PRE-MEDICATION

- Tylenol PO 650mg 1000 MG other _____
 Solumedrol 125mg IV other _____
 Benadryl 25mg 50mg other _____ IV PO
 Benadryl 50 mg or PO
 Medication _____ Dose _____ Route _____
 _____ (other) _____ (other)

WARNINGS AND PRECAUTIONS

<https://www.vimizim.com/wp-content/uploads/2018/02/Prescribing-Information.pdf>

WARNING: RISK OF ANAPHYLAXI

Life-threatening anaphylactic reactions have occurred in some patients during VIMIZIM (elosulfase alfa) infusions. Anaphylaxis, presenting as cough, erythema, throat tightness, urticaria, flushing, cyanosis, hypotension, rash, dyspnea, chest discomfort, and gastrointestinal symptoms (e.g., nausea, abdominal pain, retching, and vomiting) in conjunction with urticaria, have been reported to occur during VIMIZIM (elosulfase alfa) infusions, regardless of duration of the course of treatment. Closely observe patients during and after VIMIZIM (elosulfase alfa) administration and be prepared to manage anaphylaxis. Inform patients of the signs and symptoms of anaphylaxis and have them seek immediate medical care should symptoms occur. Patients with acute respiratory illness may be at risk of serious acute exacerbation of their respiratory compromise due to hypersensitivity reactions, and require additional monitoring.

VIMIZIM ORDERS

PATIENT WEIGHT

_____ lbs.
_____ kg

DOSAGE

- 300mg IV
 Other _____

FREQUENCY

- 2 mg/kg Weekly
 X _____ X weeks
 _____ weeks
 Other _____

REQUIRED DOCUMENTATION CHECKLIST:

- _____ Patient Demographics
 _____ Insurance Card/Information
 _____ Recent Progres notes addressing **VIMIZIM** in note
 _____ Recent labs to **include CBC, CMP**, and please send any other recent labs.
 _____ Other

ORDERING PROVIDER

Signature **X** _____ Date _____

NPI _____

Provider _____ Phone _____ Fax _____